Devyser launches the first IVDR compliant NGS assay for thalassemia and sickle cell disease testing
Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing...
News
News | May 25, 2020
Stockholm, 26 may 2020
Devyser welcomes Torbjörn Andersson as Chief Commercial Officer in charge of global sales and marketing of Devyser’s genetic tests. Torbjörn has extensive experience in building and leading international sales organisations and distributor networks in the life science industry. He joins us most recently from Biotage AB where he was the Head of EMEA Commercial Operations.
"I am excited to take on this challenge with Devyser, a growing company with a strong product portfolio and huge potential in a very interesting industry. The rapid advancements of DNA sequencing technology has opened up brand new opportunities for highly precise diagnostics. It is inspiring to be able to offer physicians the ability to personalize treatments of cancer and other serious genetic diseases using Devyser’s tests"
says Torbjörn Andersson.
As CCO, Torbjörn will lead and develop Devyser’s global sales and marketing organization and will be part of Devyser’s management team.
"Torbjörn’s solid experience in developing international sales organizations and implementing sales strategies add valuable strength as Devyser continues to expand on existing and new markets globally"
says Ulf Klangby, CEO Devyser.
Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing...
Read More
Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has...
Read More
Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA...
Read More
Devyser is proud to announce that the company has been awarded a tender by Oslo University Hospital...
Read More